Asset
Roflumilast
Arcutis Biotherapeutics Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03764475 | phase2 | completed | 2018-12-18 | 2020-10-08 | Arcutis Biotherapeutics, Inc. | Long-Term Safety of ARQ-151 Cream in Adult Subjects With Chronic Plaque Psoriasis |
| NCT04773600 | phase3 | completed | 2021-02-24 | 2022-09-29 | Arcutis Biotherapeutics, Inc. | Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (INTEGUMENT-II) |
FDA applications (2)
| Application | Type | Applicant |
|---|---|---|
| NDA 215985 | NDA | ARCUTIS BIOTHERAPEUTICS INC |
| NDA 217242 | NDA | ARCUTIS BIOTHERAPEUTICS INC |
Marketed products (4)
- ZORYVE
- ZORYVE
- ZORYVE
- ZORYVE